vs
Side-by-side financial comparison of eXp World Holdings, Inc. (EXPI) and Moderna (MRNA). Click either name above to swap in a different company.
eXp World Holdings, Inc. is the larger business by last-quarter revenue ($1.2B vs $1.0B, roughly 1.2× Moderna). eXp World Holdings, Inc. runs the higher net margin — -1.1% vs -19.7%, a 18.6% gap on every dollar of revenue. On growth, eXp World Holdings, Inc. posted the faster year-over-year revenue change (8.5% vs -45.4%). eXp World Holdings, Inc. produced more free cash flow last quarter ($11.9M vs $-880.0M). Over the past eight quarters, eXp World Holdings, Inc.'s revenue compounded faster (12.4% CAGR vs -45.0%).
eXp World Holdings, Inc. is a global cloud-based real estate services provider. It operates the eXp Realty brokerage network, leverages immersive virtual 3D campus environments to support agent collaboration and operations, serves residential and commercial real estate markets across over 20 countries, and offers complementary services including mortgage, title insurance and professional development resources for real estate practitioners.
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
EXPI vs MRNA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.0B |
| Net Profit | $-12.9M | $-200.0M |
| Gross Margin | — | 79.6% |
| Operating Margin | -1.1% | -25.6% |
| Net Margin | -1.1% | -19.7% |
| Revenue YoY | 8.5% | -45.4% |
| Net Profit YoY | -35.7% | -1638.5% |
| EPS (diluted) | $-0.08 | $-0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $954.9M | — | ||
| Q4 24 | $1.1B | $966.0M | ||
| Q3 24 | $1.2B | $1.9B | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $943.1M | — |
| Q4 25 | $-12.9M | — | ||
| Q3 25 | $3.5M | $-200.0M | ||
| Q2 25 | $-2.3M | — | ||
| Q1 25 | $-11.0M | — | ||
| Q4 24 | $-9.5M | $-1.1B | ||
| Q3 24 | $-8.5M | $13.0M | ||
| Q2 24 | $12.4M | — | ||
| Q1 24 | $-15.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 79.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | 99.9% | 72.4% | ||
| Q2 24 | 99.9% | — | ||
| Q1 24 | — | — |
| Q4 25 | -1.1% | — | ||
| Q3 25 | 0.3% | -25.6% | ||
| Q2 25 | -0.2% | — | ||
| Q1 25 | -1.1% | — | ||
| Q4 24 | -1.0% | -129.0% | ||
| Q3 24 | -0.7% | -3.8% | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | -1.9% | — |
| Q4 25 | -1.1% | — | ||
| Q3 25 | 0.3% | -19.7% | ||
| Q2 25 | -0.2% | — | ||
| Q1 25 | -1.2% | — | ||
| Q4 24 | -0.9% | -115.9% | ||
| Q3 24 | -0.7% | 0.7% | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | -1.7% | — |
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.02 | $-0.51 | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | $-0.06 | $-2.91 | ||
| Q3 24 | $-0.06 | $0.03 | ||
| Q2 24 | $0.08 | — | ||
| Q1 24 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $124.2M | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $242.8M | $9.3B |
| Total Assets | $442.5M | $12.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.2M | — | ||
| Q3 25 | $112.8M | $1.1B | ||
| Q2 25 | $94.6M | — | ||
| Q1 25 | $115.7M | — | ||
| Q4 24 | $113.6M | $1.9B | ||
| Q3 24 | $130.4M | $1.6B | ||
| Q2 24 | $108.4M | — | ||
| Q1 24 | $109.2M | — |
| Q4 25 | $242.8M | — | ||
| Q3 25 | $235.3M | $9.3B | ||
| Q2 25 | $218.4M | — | ||
| Q1 25 | $212.0M | — | ||
| Q4 24 | $204.9M | $10.9B | ||
| Q3 24 | $211.1M | $11.9B | ||
| Q2 24 | $220.3M | — | ||
| Q1 24 | $222.4M | — |
| Q4 25 | $442.5M | — | ||
| Q3 25 | $458.7M | $12.1B | ||
| Q2 25 | $481.2M | — | ||
| Q1 25 | $435.8M | — | ||
| Q4 24 | $390.7M | $14.1B | ||
| Q3 24 | $432.6M | $15.8B | ||
| Q2 24 | $457.4M | — | ||
| Q1 24 | $426.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $-847.0M |
| Free Cash FlowOCF − Capex | $11.9M | $-880.0M |
| FCF MarginFCF / Revenue | 1.0% | -86.6% |
| Capex IntensityCapex / Revenue | 0.2% | 3.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $109.0M | $-1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.8M | — | ||
| Q3 25 | $28.9M | $-847.0M | ||
| Q2 25 | $36.1M | — | ||
| Q1 25 | $39.8M | — | ||
| Q4 24 | $13.7M | $825.0M | ||
| Q3 24 | $46.0M | $-1.6B | ||
| Q2 24 | $71.1M | — | ||
| Q1 24 | $60.7M | — |
| Q4 25 | $11.9M | — | ||
| Q3 25 | $26.6M | $-880.0M | ||
| Q2 25 | $33.3M | — | ||
| Q1 25 | $37.3M | — | ||
| Q4 24 | $11.6M | $303.0M | ||
| Q3 24 | $44.4M | $-1.7B | ||
| Q2 24 | $69.7M | — | ||
| Q1 24 | $59.3M | — |
| Q4 25 | 1.0% | — | ||
| Q3 25 | 2.0% | -86.6% | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | 1.1% | 31.4% | ||
| Q3 24 | 3.6% | -92.2% | ||
| Q2 24 | 5.4% | — | ||
| Q1 24 | 6.3% | — |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.2% | 3.2% | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.2% | 54.0% | ||
| Q3 24 | 0.1% | 8.1% | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | 8.26× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -120.46× | ||
| Q2 24 | 5.75× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXPI
| North American Realty | $1.1B | 96% |
| International Realty | $42.2M | 4% |
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
